About GMI

GMI (Ganoderma microsporum immunomodulatory protein)is the culmination of 30 years of biotech research in Taiwan.
Here, we witness the metamorphosis of GMI, from the legendary medicinal roots of ganoderma, a traditional Chinese medicine, to the scientifically proven effectiveness of GMI today.

GMI Certification
The beginning Ganoderma microsporum, a new type of ganoderma native to Taiwan. GMI, the first ganoderma ingredient to achieve western medicine standards after 30 year of joint industrial, government and academic research.
Discovery of Ganoderma microsporum
In 1982, an unassumingly small ganoderma mushroom is found on a piece of willow tree, named Ganoderma microsporum due to is small spore size (compared with other types of ganoderma.
Published in Mycotaxon as a new type of ganoderma in 1989.
Discovery of GMI
Utilizing bioinformatics and gene cloning, GMI was found by cross examining the generic data of dozens of types of ganoderma in 2005.
Brand new exclusive ingredient
In 2009, the mass production and functional analyses of GMI was completed with the help of an yeast recombinant protein production platform. Database registry and structural patents for GMI were also obtained during the same year.
Basic research From genetic sequencing to the molecular structure; from quality and safety to efficacy. Decades of research stands the test of time.
Sequence to structure
structure to function: GMI has a similar 3D structure to human antibodies. The protein crystal shows a unique tetramer configuration.
3D結構連結
Stable structure
The protein structure of GMI is highly rigid and able to maintain stability in different types of solutes.
3D結構連結
Clear structure to ensure quality
the clear structure of GMI forms the basis for its effectiveness, the assurance of quality for GMI derived products.
3D結構連結
Safety assessment-genetic toxicity
  • Testing site: Level
  • GLP-compliant


Results of bacterial reverse mutation test (OECD test no. 471), in vitro chromosomal aberration test (OECD test no. 473) and mammalian erythrocyte micronucleus test (OECD test no. 474) were all negative.
Safety assessment- bio-compatibility
  • Testing site: SuperLab
  • GLP-compliant


Cytotoxicity test for mouse fibroblasts (ISO10993-5): half maximal inhibitory concentration (IC50) > 94 μg/mL
Safety assessment-acute toxicity
  • Testing site: SuperLab
  • GLP-compliant


No observed adverse effect level (NOAEL) of acute dermal toxicity test (OECD test no. 402) > 38 μg/kg body weight.
Safety assessment-acute toxicity
  • Testing site: Industrial Technology Research Institute (ITRI)


NOAEL level for mouse IV injection > 2000 μg/kg body weight.
Safety assessment-90 days toxicity
  • Testing site: Pharmaron Beijing
  • GLP-compliant


NOAEL for rat feed > 100 μg/kg body weight.
Safety assessment- teratogenicity test (fetus mutation)
  • Testing site: Pharmaron Beijing
  • GLP-compliant


NOAEL for rat feed > 100 μg/kg body weight.



The primary amino acid sequence of GMI dictates its tertiary protein properties. 44.1% of essential amino acids are found in this short 111 amino acid single chain protein.


Applied research The name of GMI is derived from scientific data. GMI has been proven to not only improve immune imbalances, but also treat cancer, aging and infection.
Immuno-modulation
GMI can modulate hormone levels of peripheral blood mononuclear cells (PBMCs), inducing effects such as the activation of NK cells and growth promotion of T cells.
Anti-cancer
GMI can inhibit EGFR to effectively control the growth of cancer cells. GMI can also induce autophagy and apoptosis of cancer cells and destroy the microenvironment of tumors to eliminate cancer cells.
Anti-aging
GMI can promote neuron growth and decrease brain inflammation to protect neurons.
COVID-19
GMI can not only modulate the immune system to maintain regular immune responses, but also regulate the production of interferon and other hormones to boost immunity.
PM2.5 pollution
GMI can regulate antioxidant enzymes such as SOD to protect against inflammation and developmental damage in progeny caused by exposure to smog.
Other research
GMI can promote stem cell growth while maintaining its pluripotency and accuracy. Besides applications in regenerative medicine, GMI can also be used in wound healing and reversing fibrosis.
The National Cancer Institute (NCI) of the US National Institute of Health (NIH) report on the effects of GMI in 60 types of human cancer cell lines:
GMI can eliminate cancer cells and inhibit cancer cell growth.
In the report, for each type of cancer, the right side line indicates the cancer-killing effect of GMI, while the left side line indicates the cancer-inhibitory effect of GMI.
GMI has different levels of inhibitory effects on leukemia, non-small cell lung cancer, colorectal cancer, CNS cancer, malignant melanoma, ovarian cancer, kidney cancer, prostate cancer and breast cancer.
The median lethal concentration (LC50) of GMI is around 20 μg/mL of GMI in cancer cells.
Mass production Innovative molecular engineering using recombinant yeast to produce GMI at an industrial scale. The fist ganoderma ingredient to achieve western medicine standards.
Innovative industrial breakthroughs
Why do rare ingredients of ancient texts end up as just myths and legends? With advances in technology, function discovery is just the first step. The key is in financially viable mass production.
Smart fermentation
Advances in biotech and AI birthed a new generation of fermentation technology. Fully automated monitoring and feedback optimizes each step in the process.
Structural certainty
the structure of a protein dictates its function. A structurally clear ingredient ensures it quality.
Recombinant protein production
The gene that codes for GMI is isolated from Ganoderma microsporum and transformed in the yeast Pichia pastoris, which is optimized through gene editing to maximize protein production.
Computer automated processing
Pharmaceutical grade automated fermentation is used in conjunction with high quality yeast to ensure that production meets the high standards of western medicine.
International certifications
Certified ISO 17025 analysis lab, #L3300, method B999 immunomodulatory protein.
Research roadmap

2022
GMI listed on the Taiwan FDA food ingredient

2021
GMI completed review for GRAS by US FDA

2021
GMI found to calm cytokine storms during severe infections

2020
GMI listed on the International Nomenclature of Cosmetic Ingredients (INCI), #35581

2020
GMI listed on the US FDA New Dietary Ingredient (NDI), #1133

2017
GMI found to repair neurons in the brain

2017
Analytical method of GMI passes TAF-ISO17025 accreditation

2014
Taiwan Ministry of Economic Affairs granted GMI as a potential new drug candidates

2013
US NIH reports GMI can effectively treat 60 types of common cancer cells

2010
3D structure of GMI registered in Protein Data Bank

2010
GMI found to treat lung cancer cells

2009
GMI registered in NIH database

2005
GMI discovered in Ganoderma microsporum using bioinformatics and genetic engineering

1989
New type of ganoderma officially named “Ganoderma microsporum”

1982
A new type of ganoderma mushroom discovered in Taiwan

Publications


about the book GMI: A novel molecule for biomedical applications - the blue ocean of oncology therapeutics

There are many lab-claimed anti-cancer ingrediants, but few that make it all the way to your doctor’s prescription, because it is very hard to achieve the trifecta of “safety”, “effectiveness”and “mass production”.

Yet today, GMI, an immunomodulatory protein originating from Ganoderma, has achieved just that! A US National Institute of Health (NIH) study has shown the suppressive effects of GMI on 9 types of cancer; Research teams from the National Taiwan University, National Yang-Ming University, Chung Shan Medical University, Taipei Medical University and others have also shown GMI, even at very small doses, to be effective against many different types of cancer, including drug resistant cancer cells and even cancer stem cells. GMI has even been shown to boost the effectiveness and reduce the negative side effects of chemotherapy, targeted therapy and immunotherapy.

Most importantly, all these anti-cancer effects can be safely realized on people.


Patent roadmap

US 11,141,458 B2：Composition and methods for promoting and treating chronic wound healing
(2021.10~)

US 11,077,168 B2：Use of an immunomodulatory protein in reducing damage caused by fine particulate matter
(2021.08~2038.04)

US 11,058,746 B2：Use of immunomodulatory protein from Ganoderma in inhibiting fibrosis
(2021.07~2035.12)

CN 1072871668：Uses of a monoclonal antibody from a fungal immunomodulatory protein
(2021.04 ~ 2036.04)

TW I723000：Use of an immunomuodulatory protein from Ganoderma in promoting neurite outgrowth
(2021.04~2035.10)

TW I670066：Use of immunomodulatory protein from Ganoderma in inhibiting fibrosis
(2019.09~2037.09)

US 9,975,931 B2：Use of an immunomuodulatory protein from Ganoderma in promoting neurite outgrowth
(2018.05~2035.10)

US 9,937,226 B2：Use of immunomodulatory protein from Ganoderma in inhibiting cancer stem cells
(2018.04~2035.12)

US 9,827,288 B2：Method for treating a refractory or relapsed lung cancer
(2017.11~2035.09)

US 9,161,964 B2：Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
(2015.10~2030.06)

US 9,018,171 B2：Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
(2015.04~2030.06)

TW I 414307：Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
(2013.11~2030.12)

US 8,476,238 B2：Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
(2013.07~2030.11)

US 7,601,808 B2：An immunomodulatory protein from Ganoderma microsporum
(2009.10~2026.12)

TW I299735：An immunomodulatory protein from Ganoderma microsporum
(2008.8~2026.01)

Contact us
Location

8F.-1, No. 12, Ln. 270, Sec. 3, Beishen Rd., Shenkeng Dist., New Taipei City 222 , Taiwan (R.O.C.)

Phone

+886-2-2662-0148

Email

service@mycomagic.com.tw